Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces evoked pain in healthy volunteers, a randomized, double‐blind, placebo‐controlled, crossover study

Ähnliche Einträge

• Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial
  von: Nathaniel M. Schuster, et al.
  Veröffentlicht: (2025)
• E‐52862—A selective sigma‐1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double‐blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy
  von: Rafael Gálvez, et al.
  Veröffentlicht: (2024)
• Response to the commentary by Johnson et al. on ‘Movement‐evoked pain is not associated with pain at rest or physical function in knee osteoarthritis’
  von: J. A. Lozano‐Meca, et al.
  Veröffentlicht: (2024)
• The effect of stretching intensity on pain sensitivity: A randomized crossover study on healthy adults
  von: Morten Pallisgaard Støve, et al.
  Veröffentlicht: (2024)
• Movement‐evoked pain is not associated with pain at rest or physical function in knee osteoarthritis
  von: José Antonio Lozano‐Meca, et al.
  Veröffentlicht: (2024)